Skip to content

Live Events
Sign Up / Login

Live Events
Sign Up / Login

MEC Basic Full List View

By pinki@katapult.biz / February 16, 2025

MEC Basic

Speciality

Author / Speaker

Title

Type of Media

Events

Search Everything

«
1
2
3
4
5
…
62
»

New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

Mark Pegram, MD

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Mariana Chavez MacGregor, MD, MSc, FASCO

Esophageal and Gastric Cancer: Moving to a More Personalized Approach

Esophageal and Gastric Cancer: Moving to a More Personalized Approach

Ahmed Zakari, MD

After ESMO 2024: What Novel Therapies Are in Use and on Development for Pancreas and Biliary Cancers?

After ESMO 2024: What Novel Therapies Are in Use and on Development for Pancreas and Biliary Cancers?

Caio Max Rocha-Lima, MD, MS

Novel Advances in Colon and Rectal Carcinomas

Novel Advances in Colon and Rectal Carcinomas

Axel Grothey, MD

Integration of Palliative Care in Oncology

Integration of Palliative Care in Oncology

Roberto Ochoa, MD

Integrative Approaches to Improve Sleep During Cancer Treatment and Survivorship

Integrative Approaches to Improve Sleep During Cancer Treatment and Survivorship

Ashwin Mehta, MD, MPH

Lifestyle Modifications in Reducing Risk of Recurrence

Lifestyle Modifications in Reducing Risk of Recurrence

Tracy E. Crane, PhD, RDN

Thyroid and Thymic Carcinomas: Where Are We Know?

Thyroid and Thymic Carcinomas: Where Are We Know?

Martin Dietrich, MD, PhD

Novel Advances for Osteosarcomas in 2025

Novel Advances for Osteosarcomas in 2025

Gina D’Amato, MD

State-of-the-Art Management in Early and Metastatic Melanoma 2025

State-of-the-Art Management in Early and Metastatic Melanoma 2025

Lilit Karapetyan, MD, MS, FACP

Antibody Drug Conjugates for HER2 Negative Breast Cancer: Advancing Breast Cancer Management

Antibody Drug Conjugates for HER2 Negative Breast Cancer: Advancing Breast Cancer Management

Suchita Pakkala, MD

Colorectal Cancer Genomic Profiling, Tumor-Informed or Tumor Naïve. Primetime and Utility?

Colorectal Cancer Genomic Profiling, Tumor-Informed or Tumor Naïve. Primetime and Utility?

Ahmed Zakari, MD

Esophageal and Gastric Carcinomas: Moving the Bar Up after ESMO 2024

Esophageal and Gastric Carcinomas: Moving the Bar Up after ESMO 2024

Mike Cusnir, MD

HCC and Pancreatic Cancer: Novel Therapies after ASCO and ESMO 2024

HCC and Pancreatic Cancer: Novel Therapies after ASCO and ESMO 2024

Mitesh Borad, MD

What is New After ASCO and ESMO 2024 in Colon and Rectal Cancer Management?

What is New After ASCO and ESMO 2024 in Colon and Rectal Cancer Management?

Fernando de Zarraga, MD

New Endocrine and Targeted Agents for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

New Endocrine and Targeted Agents for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Maria Theodoulou, MD

Post-Neoadjuvant Therapy after Residual Disease: How to Approach This Problem?

Post-Neoadjuvant Therapy after Residual Disease: How to Approach This Problem?

Lauren Carcas, MD

Progress in Neoadjuvant Therapy for Breast Cancer: Reviewing the Role of Immunotherapy, Endocrine and Anti-Her-2 Therapy

Progress in Neoadjuvant Therapy for Breast Cancer: Reviewing the Role of Immunotherapy, Endocrine and Anti-Her-2 Therapy

Gregory Vidal, MD

B-cell and T-cell NHL Challenges

B-cell and T-cell NHL Challenges

Eduardo Sotomayor, MD

Multiple Myeloma in 2024

Multiple Myeloma in 2024

Melissa Alsina, MD

Updates in CML and CLL

Updates in CML and CLL

Javier Pinilla-Ibarz, MD

Small-Cell Lung Cancer

Small-Cell Lung Cancer

Triparna Sen, PhD

Targeted Therapy in NSCLC

Targeted Therapy in NSCLC

Bruna Pellini, MD

Immunotherapy in NSCLC: Advanced Disease and Resistance

Immunotherapy in NSCLC: Advanced Disease and Resistance

George Simon, MD

Prostate Cancer: What is the Best Combination Therapy?

Prostate Cancer: What is the Best Combination Therapy?

Chandler H. Park, MD

Gynecologic Malignancies: New Therapeutic Developments

Gynecologic Malignancies: New Therapeutic Developments

Alexander B. Olawaiye, MD

Updates in Kidney and Bladder Cancers: Immunotherapy and Targeted Therapy

Updates in Kidney and Bladder Cancers: Immunotherapy and Targeted Therapy

Pedro Barata, MD

Latest Advances in Gastrointestinal Cancers

Latest Advances in Gastrointestinal Cancers

Edward Kim, MD, PhD

Therapeutic Advances in Gynecologic Oncology

Therapeutic Advances in Gynecologic Oncology

Rebecca Brooks, MD

Displaying 61 - 90 of 1,833

Post navigation

← Previous View

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Useful Links

Library
Live Events

Categories

MEC Basic
MEC Plus
Purchased

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok